| Size | Price | |
|---|---|---|
| Other Sizes |
Purity: =99.69%
| Targets |
Magnesium sulfate heptahydrate does not have a specific pharmacological target. Magnesium ions (Mg2+) are essential for numerous physiological processes including enzyme activation, neuromuscular transmission, cardiovascular function, and bone metabolism. As a magnesium salt, magnesium sulfate provides bioavailable magnesium that can be absorbed and utilized by the body. In medical applications, magnesium sulfate is used as an anticonvulsant for eclampsia and pre-eclampsia, as a tocolytic agent, and for the treatment of magnesium deficiency.
|
|---|---|
| ln Vitro |
As a pharmaceutical compound, magnesium sulfate heptahydrate is not typically evaluated for in vitro activity in the traditional sense. Its pharmacological effects are mediated through the actions of magnesium ions, which regulate numerous physiological processes. In vitro, magnesium ions are required for the activity of many enzymes and for proper cell function in culture systems. The compound is used as a source of magnesium in cell culture media and biochemical assays.
|
| ln Vivo |
Magnesium sulfate heptahydrate is used in vivo as a pharmaceutical agent, particularly as an anticonvulsant for the prevention and management of eclamptic fits. It is administered intravenously or intramuscularly for this indication. Magnesium sulfate is also used as a tocolytic agent to prevent premature labor and as a treatment for magnesium deficiency. The compound is generally administered under medical supervision for these indications.
|
| Enzyme Assay |
Non-cell-based protocols for magnesium sulfate heptahydrate typically involve the preparation of solutions for pharmaceutical or laboratory applications. A standard protocol includes: dissolving the appropriate amount of magnesium sulfate heptahydrate in water or buffer, adjusting the pH if necessary, and sterilizing by filtration or autoclaving. The compound is also used in analytical chemistry as a drying agent and as a reagent in various chemical reactions.
|
| Cell Assay |
Cell-based assays with magnesium sulfate heptahydrate typically involve cell culture applications where magnesium ions are essential for cell function. A representative protocol includes: preparing cell culture medium supplemented with magnesium sulfate at the appropriate concentration (typically 0.8–1.2 mM for mammalian cell culture), culturing cells in the medium, and assessing cell viability, proliferation, and function. Magnesium is required for the activity of numerous enzymes and for proper cellular metabolism.
|
| Animal Protocol |
In vivo animal studies with magnesium sulfate heptahydrate are conducted for various research applications including the study of eclampsia, preterm labor, and magnesium deficiency. A typical protocol involves administering magnesium sulfate via intravenous, intramuscular, or intraperitoneal injection at doses determined from pharmacokinetic studies. Physiological and biochemical parameters are monitored to assess the effects of magnesium administration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of magnesium sulfate have been characterized for clinical use. Following intravenous administration, magnesium distributes rapidly throughout the extracellular fluid, with approximately 30–40% bound to plasma proteins. Magnesium is primarily excreted by the kidneys, with the rate of excretion increasing with increasing serum magnesium concentrations. The half-life of magnesium sulfate is approximately 1.5–2 hours in patients with normal renal function.
|
| Toxicity/Toxicokinetics |
Magnesium sulfate heptahydrate is a pharmaceutical compound that has been well characterized for safety in clinical use. Common side effects include flushing, sweating, hypotension, and sedation at therapeutic doses. At high doses, magnesium sulfate can cause respiratory depression, cardiac arrest, and neuromuscular blockade. The compound is contraindicated in patients with heart block, myocardial damage, or renal failure.
|
| References | |
| Additional Infomation |
Magnesium sulfate heptahydrate is the heptahydrate form of magnesium sulfate. It has laxative and constipation-relieving properties. It is a magnesium salt and also a hydrate. It contains magnesium sulfate. Epsom salt (magnesium sulfate) is a mineral with the chemical formula MgS6+O4·7H2O or Mg(SO4)·7H2O. The symbol of the International Mineralogical Association (IMA) is Esm.
Magnesium sulfate heptahydrate (CAS 10034-99-8) is a pharmaceutical and laboratory reagent that meets the analytical specifications of Ph. Eur., BP, USP, and FCC. It is widely known as Epsom salts and is used as an anticonvulsant for eclampsia, as a tocolytic agent, and as a magnesium supplement. The compound is also used in cell culture media, as a drying agent in chemical synthesis, and as a reagent in various biochemical applications. Its high purity (99.5–100.5%) makes it suitable for pharmaceutical and analytical applications. |
| Molecular Formula |
MGSO4.7H2O
|
|---|---|
| Molecular Weight |
246.47
|
| Exact Mass |
246.01
|
| CAS # |
10034-99-8
|
| Related CAS # |
7487-88-9 (Parent)
|
| PubChem CID |
24843
|
| Appearance |
White to off-white solid powder
|
| Density |
2.66
|
| Boiling Point |
330ºC at 760 mmHg
|
| Melting Point |
1124°C
|
| Vapour Pressure |
3.35E-05mmHg at 25°C
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
13
|
| Complexity |
62.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O.O.O.O.O.O.O.[O-]S(=O)(=O)[O-].[Mg+2]
|
| InChi Key |
WRUGWIBCXHJTDG-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/Mg.H2O4S.7H2O/c;1-5(2,3)4;;;;;;;/h;(H2,1,2,3,4);7*1H2/q+2;;;;;;;;/p-2
|
| Chemical Name |
magnesium;sulfate;heptahydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~200 mg/mL (~811.46 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0573 mL | 20.2864 mL | 40.5729 mL | |
| 5 mM | 0.8115 mL | 4.0573 mL | 8.1146 mL | |
| 10 mM | 0.4057 mL | 2.0286 mL | 4.0573 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA